News-Medical.Net on MSN

Rockefeller scientists engineer next-generation antibody to replace IVIG therapy

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...
WDAF-TV

GC Biopharma Highlights IVIG Innovation and Investigator-Initiated Research as Science to Solutions Partner at the Fall 2025 CIIC Conference

TEANECK, N.J., Oct. 13, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, participated as the exclusive Science to Solutions Partner at the 2025 Consortium of ...

GC Biopharma Supports New Insights into Education, Safety, and Patient Outcomes in Ig Therapy Care at the 2025 IgNS Annual Meeting

GC Biopharma USA, Inc., a leader in plasma-derived products, announced today its support of data analysis and publication of the 2025 Immunoglobulin National Society (IgNS) Patient 360 Longitudinal ...
Nasdaq

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin ...